Douglas J. Swirsky Joins Fibrocell Board

  Douglas J. Swirsky Joins Fibrocell Board

               Brings Extensive Experience with Capital Markets

Business Wire

EXTON, Pa. -- March 5, 2013

Fibrocell Science, Inc. (OTC: FCSC) announced today that Douglas J. Swirsky,
CPA, CFA, joined its Board of Directors. Since 2006, Mr. Swirsky has served as
Senior Vice President, Chief Financial Officer, Treasurer and Corporate
Secretary of GenVec, Inc. Mr. Swirsky previously held investment banking
positions at UBS, PaineWebber, Morgan Stanley, and Legg Mason. Prior to
joining GenVec, Mr. Swirsky was with Stifel Nicolaus where he served as a
Managing Director and the Head of Life Sciences Investment Banking. His
experience also includes positions in public accounting and consulting.

“Doug brings extensive and wide-ranging financial expertise to our Board,”
said David Pernock, CEO and Board Chair, Fibrocell Science. “His experience in
life sciences and his relationship with the capital markets is an excellent
fit with our strategic direction. We’re delighted to welcome him as a new
Board member.”

GenVec, Inc. is a biopharmaceutical company that uses differentiated,
proprietary technologies to create superior therapeutics and vaccines. In his
current position, Mr. Swirsky oversees all financial aspects of GenVec’s
operations and works closely with the CEO and executive team on business
strategy. He received his B.S. in Business Administration from Boston
University and his M.B.A. from the Kellogg School of Management at
Northwestern University. Mr. Swirsky is a member of the Board of Directors of
PolyMedix, Inc.

About Fibrocell Science, Inc.

Fibrocell Science, Inc. (FCSC) is an autologous cellular therapeutic company
focused on the development of innovative products for aesthetic, medical and
scientific applications. Fibrocell Science is committed to advancing the
scientific, medical and commercial potential of autologous skin and tissue, as
well as its innovative cellular processing technology and manufacturing
excellence. For additional information, please visit www.fibrocellscience.com.

Forward-Looking Statements

All statements in this press release that are not based on historical fact are
“forward-looking statements” within the meaning of the Private Securities
Litigation Reform Act of 1995 and the provisions of Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the Securities Exchange
Act of 1934, as amended. While management has based any forward-looking
statements contained herein on its current expectations, the information on
which such expectations were based may change. These forward-looking
statements rely on a number of assumptions concerning future events and are
subject to a number of risks, uncertainties, and other factors, many of which
are outside of the Company’s control, that could cause actual results to
materially differ from such statements. Such risks, uncertainties, and other
factors include, but are not necessarily limited to, those set forth under
Item 1A “Risk Factors” in the Company’s Annual Report on Form 10-K for the
year ended December 31, 2011, as updated in “Item 1A. Risk Factors” in the
Company’s Quarterly Reports on Form 10-Q filed since the annual report. The
Company operates in a highly competitive and rapidly changing environment,
thus new or unforeseen risks may arise. Accordingly, investors should not
place any reliance on forward-looking statements as a prediction of actual
results. The Company disclaims any intention to, and undertakes no obligation
to, update or revise any forward-looking statements. Readers are also urged to
carefully review and consider the other various disclosures in the Company’s
public filings with the SEC.

Contact:

Media
Marina Maher Communications, LLC
Heather Adamson, 212-485-6806
hadamson@mahercomm.com
or
Investors
Fibrocell Science Desk
Redington, Inc.
212-926-1733
fibrocell@redingtoninc.com
203-222-7399
 
Press spacebar to pause and continue. Press esc to stop.